Company news
Immunome, Inc. (NASDAQ:IMNM) news
Immunome, Inc. news releases on 6ix. Latest, Dec 1, 2021: Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
Press releases — page 3
Immunome Expects IMM-BCP-01 Antibody Cocktail To Neutralize the SARS-CoV-2 Omicron Variant
November 30, 2021
Immunome Announces Submission of an Investigational New Drug (IND) Application for IMM-BCP-01 for the Treatment of COVID-19
November 28, 2021
Immunome Reports Third Quarter 2021 Financial Results
November 14, 2021
Immunome to Present at the Stifel Healthcare Conference
November 8, 2021
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
October 19, 2021
Immunome Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 6, 2021
Immunome to Present Preclinical Data on Anti IL-38 Antibody Program at the American Association for Cancer Research NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 29, 2021
Immunome to Present at the Cantor Global Healthcare Conference
September 21, 2021
Immunome to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 14, 2021
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing
September 6, 2021
Immunome Reports Second Quarter 2021 Financial Results
August 18, 2021
Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
July 19, 2021
Immunome to Present at the Ladenburg Thalmann 2021 Healthcare Conference
July 5, 2021
Immunome Appoints Andrew Badley, M.D., to COVID-19 Advisory Board
June 29, 2021
Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors
June 16, 2021
Immunome to Present at the Jefferies Virtual Healthcare Conference
May 26, 2021
Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern
May 19, 2021
Immunome Reports First Quarter 2021 Financial Results
May 11, 2021
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
April 25, 2021
Immunome Announces $27 Million Private Placement
April 25, 2021
Immunome Appoints Corleen Roche as Chief Financial Officer
April 19, 2021
Immunome Appoints Dr. Dennis Giesing as Chief Development Officer
March 29, 2021
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
March 24, 2021
Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies
March 22, 2021
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
February 17, 2021
Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus
January 31, 2021
Immunome Provides Organizational Update: Appoints Richard Baron to its Board of Directors and Sandra Stoneman as Chief Legal Officer and Corporate Secretary
December 9, 2020
Immunome Reports Third Quarter 2020 Financial Results and Significant Progress
November 16, 2020
Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
October 12, 2020
Immunome Announces Pricing of Upsized Initial Public Offering
September 30, 2020